170 related articles for article (PubMed ID: 11408522)
1. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats.
Andrade-Gordon P; Derian CK; Maryanoff BE; Zhang HC; Addo MF; Cheung Wm ; Damiano BP; D'Andrea MR; Darrow AL; de Garavilla L; Eckardt AJ; Giardino EC; Haertlein BJ; McComsey DF
J Pharmacol Exp Ther; 2001 Jul; 298(1):34-42. PubMed ID: 11408522
[TBL] [Abstract][Full Text] [Related]
2. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates.
Derian CK; Damiano BP; Addo MF; Darrow AL; D'Andrea MR; Nedelman M; Zhang HC; Maryanoff BE; Andrade-Gordon P
J Pharmacol Exp Ther; 2003 Feb; 304(2):855-61. PubMed ID: 12538843
[TBL] [Abstract][Full Text] [Related]
3. RWJ-58259: a selective antagonist of protease activated receptor-1.
Damiano BP; Derian CK; Maryanoff BE; Zhang HC; Gordon PA
Cardiovasc Drug Rev; 2003; 21(4):313-26. PubMed ID: 14647534
[TBL] [Abstract][Full Text] [Related]
4. Oral administration of the thrombin receptor antagonist E5555 (atopaxar) attenuates intimal thickening following balloon injury in rats.
Kogushi M; Matsuoka T; Kuramochi H; Murakami K; Kawata T; Kimura A; Chiba K; Musha T; Suzuki S; Kawahara T; Kajiwara A; Hishinuma I
Eur J Pharmacol; 2011 Sep; 666(1-3):158-64. PubMed ID: 21635884
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
Wu CC; Teng CM
Eur J Pharmacol; 2006 Sep; 546(1-3):142-7. PubMed ID: 16890935
[TBL] [Abstract][Full Text] [Related]
6. The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs.
Kogushi M; Matsuoka T; Kawata T; Kuramochi H; Kawaguchi S; Murakami K; Hiyoshi H; Suzuki S; Kawahara T; Kajiwara A; Hishinuma I
Eur J Pharmacol; 2011 Apr; 657(1-3):131-7. PubMed ID: 21300059
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of protease activated receptor-2 (PAR-2) in balloon-injured rat carotid artery.
Damiano BP; D'Andrea MR; de Garavilla L; Cheung WM; Andrade-Gordon P
Thromb Haemost; 1999 May; 81(5):808-14. PubMed ID: 10365757
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent peptide-mimetic antagonists for the human thrombin receptor, protease-activated receptor-1 (PAR-1).
Maryanoff BE; Zhang HC; Andrade-Gordon P; Derian CK
Curr Med Chem Cardiovasc Hematol Agents; 2003 Mar; 1(1):13-36. PubMed ID: 15317288
[TBL] [Abstract][Full Text] [Related]
10. The contribution of thrombin-induced platelet activation to thrombus growth is diminished under pathological blood shear conditions.
Lee H; Sturgeon SA; Jackson SP; Hamilton JR
Thromb Haemost; 2012 Feb; 107(2):328-37. PubMed ID: 22187047
[TBL] [Abstract][Full Text] [Related]
11. Discovery and optimization of a novel series of thrombin receptor (par-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates.
Zhang HC; Derian CK; Andrade-Gordon P; Hoekstra WJ; McComsey DF; White KB; Poulter BL; Addo MF; Cheung WM; Damiano BP; Oksenberg D; Reynolds EE; Pandey A; Scarborough RM; Maryanoff BE
J Med Chem; 2001 Mar; 44(7):1021-4. PubMed ID: 11297447
[No Abstract] [Full Text] [Related]
12. Adenovirus-mediated transfer of human placental ectonucleoside triphosphate diphosphohydrolase to vascular smooth muscle cells suppresses platelet aggregation in vitro and arterial thrombus formation in vivo.
Furukoji E; Matsumoto M; Yamashita A; Yagi H; Sakurai Y; Marutsuka K; Hatakeyama K; Morishita K; Fujimura Y; Tamura S; Asada Y
Circulation; 2005 Feb; 111(6):808-15. PubMed ID: 15699260
[TBL] [Abstract][Full Text] [Related]
13. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
Bilodeau ML; Hamm HE
J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist.
Gunnet JW; Wines P; Xiang M; Rybczynski P; Andrade-Gordon P; de Garavilla L; Parry TJ; Cheung WM; Minor L; Demarest KT; Maryanoff BE; Damiano BP
Eur J Pharmacol; 2008 Aug; 590(1-3):333-42. PubMed ID: 18599033
[TBL] [Abstract][Full Text] [Related]
15. Aprotinin inhibits protease-dependent platelet aggregation and thrombosis.
Khan TA; Bianchi C; Voisine P; Sandmeyer J; Feng J; Sellke FW
Ann Thorac Surg; 2005 May; 79(5):1545-50. PubMed ID: 15854931
[TBL] [Abstract][Full Text] [Related]
16. Direct vascular effects of protease-activated receptor type 1 agonism in vivo in humans.
Gudmundsdóttir IJ; Megson IL; Kell JS; Ludlam CA; Fox KA; Webb DJ; Newby DE
Circulation; 2006 Oct; 114(15):1625-32. PubMed ID: 17015787
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor.
Andrade-Gordon P; Maryanoff BE; Derian CK; Zhang HC; Addo MF; Darrow AL; Eckardt AJ; Hoekstra WJ; McComsey DF; Oksenberg D; Reynolds EE; Santulli RJ; Scarborough RM; Smith CE; White KB
Proc Natl Acad Sci U S A; 1999 Oct; 96(22):12257-62. PubMed ID: 10535908
[TBL] [Abstract][Full Text] [Related]
18. Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice.
Major CD; Santulli RJ; Derian CK; Andrade-Gordon P
Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):931-9. PubMed ID: 12676802
[TBL] [Abstract][Full Text] [Related]
19. Protease-activated receptors in cardiovascular diseases.
Leger AJ; Covic L; Kuliopulos A
Circulation; 2006 Sep; 114(10):1070-7. PubMed ID: 16952995
[TBL] [Abstract][Full Text] [Related]
20. Role of the endothelium in the vascular effects of the thrombin receptor (protease-activated receptor type 1) in humans.
Gudmundsdóttir IJ; Lang NN; Boon NA; Ludlam CA; Webb DJ; Fox KA; Newby DE
J Am Coll Cardiol; 2008 May; 51(18):1749-56. PubMed ID: 18452780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
